August 16, 2026 — CanSino Biologics Inc. ("CanSinoBIO", 688185. SH, 06185.HK) announced that the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (for people aged six years old and above) (the "Td5cp Adolescent and Adult") has recently been accepted by the National Medical Products Administration (NMPA) of China.

The Td5cp Adolescent and Adult is intended for booster immunization against diphtheria, tetanus and acellular pertussis for adolescents and adults aged six years old and above. The acceptance of the NDA marks further progress in CanSinoBIO's innovative pertussis vaccine development and provides a new option for booster immunization among adolescents and adults.

Pertussis is an acute respiratory infectious disease caused by Bordetella pertussis, and individuals of all ages may be infected¹. In recent years, an increasing number of countries and regions worldwide have reported rising pertussis cases². Relevant data showed that more than 470,000 pertussis cases were reported in China in 2024³. Vaccination remains one of the most effective measures for preventing pertussis. However, as disease epidemiology evolves, pertussis infections among adolescents and adults and their implications for pertussis transmission prevention and control in infants have received increasing attention. The importance of booster immunization for adolescents and adults has therefore become increasingly recognized⁴.

In April 2026, CanSinoBIO's Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed for infants (below 2 years old) (the "DT3cP Infant"), Tripecia® received NDA approval through the NMPA's Priority Review pathway, representing an important milestone in the development of component-based pertussis vaccine technologies in China. Compared with the DT3cP Infant containing three pertussis antigens — pertussis toxin (PT), filamentous hemagglutinin (FHA), and pertactin (PRN) — the Td5cp Adolescent and Adult additionally incorporates FIM2 and FIM3 antigens. Through independent purification of individual pertussis antigens and precise antigen-ratio design, the product is expected to optimize quality control and batch-to-batch consistency further, laying a foundation for extending innovative component-based pertussis vaccine technology to broader age groups.

In May 2026, the Td5cp Adolescent and Adult was included in the NMPA's priority review procedure. Upon approval, the product is expected to complement the approved Tripecia® (DT3cP Infant), further advancing CanSinoBIO's lifecycle immunization strategy by extending innovative pertussis vaccine protection from infancy to adolescence and adulthood.

Going forward, CanSinoBIO will continue to strengthen its R&D capabilities in innovative bacterial vaccines, accelerate the translation of innovative vaccine research achievements, and expand its innovative vaccine portfolio to support broader immunization coverage and protection throughout life.

References:

1.Chinese Center for Disease Control and Prevention, "Pertussis Prevention and Control: Public Health Education," December 11, 2024, https://www.chinacdc.cn/jkkp/crb/ycr/202412/t20241211_303248.html.

 2.Chinese Preventive Medicine Association, Vaccine and Immunization Branch of Chinese Preventive Medicine Association, "Expert Consensus on China Pertussis Action Plan," Chinese Journal of Epidemiology, 2021, 42(6): 955-965.

 3.World Health Organization (WHO), "Pertussis reported cases and incidence," WHO Immunization Data, https://immunizationdata.who.int/global/wiise-detail-page/pertussis-reported-cases-and-incidence?CODE=CHN&YEAR=.

 4.Chinese Preventive Medicine Association, Vaccine and Immunization Branch of Chinese Preventive Medicine Association, "Expert Consensus on China Pertussis Action Plan," Chinese Journal of Epidemiology, 2021, 42(6): 955-965.

Disclaimer:

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.